Claravant Analytics LLC is aiming to change the biotech investment ecosystem by leveling the playing field for public investors that don't have access to confidential information. The firm plans to serve as a third-party intermediary that signs non-disclosure agreements with companies to gain access to confidential information, which it then will analyze to rate therapeutic programs.

The company debuted in April and already is evaluating programs for multiple clients, according to CEO Chris Plaford.